Peptides DB
Research-centric peptide and protocol reference hub

Degarelix record · updated 6h ago

Healing & recoveryGrade A · human clinicalResearch use only
All 19 studiesJump to the evidenceCompare
What is Degarelix used for?

Degarelix is a synthetic peptide that functions as a gonadotropin-releasing hormone (GnRH) antagonist. By competitively inhibiting GnRH receptors in the pituitary gland, degarelix reduces the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased testosterone production in the testes. This mechanism is particularly beneficial in the treatment of hormone-sensitive conditions such as prostate cancer, where testosterone can promote tumor growth.

How it works: GnRH receptor antagonist

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection

Development stage

where Degarelix sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 89 registered trials. It describes the research record, not a recommendation.

Identity
NameDegarelix
Chain length—
Molecular weight1,632.3 Da
FormulaC82H103ClN18O16
Structure typeNot established
ClassMetabolic
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 16136245. No verified residue count for this compound.

Pharmacology
MechanismGnRH receptor antagonist
RouteSubcutaneous injection
Half-life~1 month
Time to peak1–2 days
DurationLong-acting
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 19, 2026. How this works →
Research stats
Total studies19
Human / animal / cellular16 / 1 / 0
Highest trial phasePhase 2
Years covered2016–2026
Latest study5d ago
Publication history
20162026
Research funding
11 NIH projects · $3.5M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports1,126
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

19 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Effect of neoadjuvant androgen deprivation therapy on prostate and tumor morphology prior to MRI-guided transurethral ultrasound ablation of prostate cancer.
FindingPSA declined by 87% (-7.6 ng/mL; 95% CI. -9.7 to -5.7; p < 0.001)
Human2026Full text read0.80
Fewer Injections and Lower Drug Costs With Long-Acting GnRH Depot Formulations: A Nationwide Analysis of 2.3 Million Patient-Years in Japan.
FindingInjections decreased by 21.5%, from 1,275,081 to 1,000,324.
Human2026Full text read0.90
Fewer Injections and Lower Drug Costs With Long-Acting GnRH Depot Formulations: A Nationwide Analysis of 2.3 Million Patient-Years in Japan.
FindingInjections decreased by 21.5%, from 1,275,081 to 1,000,324.
Human2023Full text read0.90
Bone-related adverse events of hormonal therapy: A pharmacovigilance study based on the Food &amp; Drug Administration Adverse Event Reporting System.
FindingNot reported in abstract.
review2026Full text read0.70
Peribronchial cuffing: an underrecognized pattern of prostate carcinoma metastases to the lung.
Finding55% of patients died within a median of 5.3 months from radiographic detection.
Human2023Full text read0.80
Pulmonary tumor thrombotic microangiopathy associated with prostate cancer achieving over 10-year survival: a case report.
FindingNot reported in abstract.
Human2026Full text read0.70
B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities across Patient Groups with Prostate Cancer.
FindingHigh B7-H3 expression in HSPCs portended adverse OS (HR, 1.30; CI, 1.15-1.46; q < 0.0001).
Human2023Full text read0.90
A novel model to study the impact of gender-affirming therapy on bone in young male mice.
FindingNot reported in abstract.
Animal2026Full text read0.70
Apalutamide-Induced Pneumonitis Presenting as Severe Hypoxemic Respiratory Failure in Metastatic Prostate Cancer: A Case Report.
TakeawayClinicians should be vigilant for signs of pneumonitis in patients receiving apalutamide, as early intervention may improve outcomes.
Human2026Full text read0.70
Ultrasound localisation microscopy tracks testicular microvascular adaptations to endocrine function in male infertility.
FindingVessel density p < 0.001 and diameter p < 0.01 were reduced in azoospermia irrespective of treatment.
Human2026Full text read0.80
Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy. The BLADE study
Findingr=0.64, p=0.001 for FSH and appendicular lean mass index/fat body mass ratio.
Human2023Full text read0.80
Gonadotropin-releasing hormone antagonism reduces paedophilic interest through increased cerebellar activity
Findingr=-0.740, p<0.001 for correlation between cerebellar activation and reduction in paedophilic interest after degarelix.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Degarelix will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Degarelix is discussed should be drawn from it.